NGAL (Neutrophil Gelatinase-Associated Lipocalin) as an early biomarker of nephropathy in patients with type 2 diabetes
Open Access
- 12 July 2023
- journal article
- research article
- Published by Taylor & Francis in Alexandria Journal of Medicine
- Vol. 59 (1) , 52-58
Abstract
No abstract availableKeywords
Funding Information
- organization for the submitted work
This publication has 23 references indexed in Scilit:
- Diabetic nephropathy – complications and treatmentInternational Journal of Nephrology and Renovascular Disease, 2014
- Evaluation of the cisplatin nephrotoxicity using the urinary neutrophil gelatinase-associated lipocalin (NGAL) in patients with head and neck cancerBrazilian Journal of Nephrology, 2014
- Non-albuminuric renal disease among subjects with advanced stages of chronic kidney failure related to type 2 diabetes mellitusRenal Failure, 2013
- Renal Duplex Sonographic Evaluation of Type 2 Diabetic PatientsJournal of Ultrasound in Medicine, 2013
- Kidney Disease and Increased Mortality Risk in Type 2 DiabetesJournal of the American Society of Nephrology, 2013
- The emerging concept of chronic kidney disease without clinical proteinuria in diabetic patientsDiabetes & Metabolism, 2012
- Clinical implication of urinary tubular markers in the early stage of nephropathy with type 2 diabetic patientsDiabetes Research and Clinical Practice, 2012
- Novel Insights into the Relationship Between Glomerular Pathology and Progressive Kidney DiseaseAdvances in Chronic Kidney Disease, 2012
- Neutrophil Gelatinase-Associated Lipocalin (NGAL): an early marker for diabetic nephropathyInternational Journal of Diabetes in Developing Countries, 2012
- Urinary Liver-Type Fatty Acid-Binding Protein Predicts Progression to Nephropathy in Type 1 Diabetic PatientsDiabetes Care, 2010